SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Treatment with rituximab (RTX), a monoclonal antibody targeting CD20, constitutes an important therapeutic strategy for patients with inflammatory rheumatic diseases. Some recent reports have already highlighted the risk of SARS-CoV-2 infection in patients treated with RTX.\(^1\)\(^-\)\(^4\) Besides the risk of a more severe disease course during B cell depleting therapy, a major concern relates to a risk of reduced immunogenicity of vaccination. Therefore, the question arises if patients should withhold or interrupt RTX therapy around COVID-19 vaccination or delay vaccination. To address this question, we have assessed antibody response and T cell mediated immune response to the BNT162b2 (Pfizer/BioNTech) vaccine in patients undergoing RTX treatment at the end of the treatment interval.

Five patients under regular and recent RTX treatment were selected for COVID-19 vaccination with BNT162b2 (Pfizer/BioNTech). A detailed description of the methods and the patient characteristics (online supplemental table S1) can be found in the online supplemental material. The last RTX infusion was administered between 4 and 12 months ago (online supplemental figure S1). At the time of the vaccination, peripheral CD19\(^+\) B cells could only be detected in two patients (online supplemental table S2). Antibodies against the SARS-CoV-2 nucleocapsid (NC) and the receptor-binding domain (RBD) of the spike protein were analysed 12–23 days following the second
Humoral immune response in rituximab-treated patients. Antibodies to the receptor-binding domain (RBD) of the viral spike (S) protein was determined using an anti-SARS-CoV-2 S immunoassay. Rituximab-treated patients with detectable CD19+ peripheral B cells are labelled green. Vaccinated and not vaccinated healthy individuals served as a positive and negative control group. HC, healthy controls.

To determine a SARS-CoV-2 specific T cell reactivity, we measured interferon (IFN)-γ response to SARS-CoV-2 peptides in our patient cohort and control groups. All groups showed IFN-γ secretion on non-specific T cell stimulation of heparinised whole blood with mitogen. After stimulation with two different SARS-CoV-2 specific antigen mixes, IFN-γ response could be detected in the vaccinated healthy control group as well as in the patient cohort, independent of the humoral immune response (online supplemental figure S2). Of note, lower levels of IFN-γ were detected in one patient who concomitantly received intermediate prednisone dose.

In the current report, we could demonstrate that B cell depleting therapy with RTX affects the humoral immune response to SARS-CoV-2 vaccination in B cell depleted patients. However, humoral immune response was observed in patients who had measurable peripheral B cells following RTX treatment. These data are in line with very recent reports showing that RTX treatment might affect the antibody response to SARS-CoV-2 vaccination. However, we could here reveal a T cell mediated immune response even in B cell depleted patients. It will be important to understand if T cell immunity is important or possibly even sufficient to protect patients against infection with the virus on vaccination. Our data also indicate that RTX treatment may not have to preclude SARS-CoV-2 vaccination, since a cellular immune response will be mounted even in the absence of circulating B cells. Alternatively, in patients with stable disease delaying RTX treatment until after the second vaccination may be warranted and, therefore, vaccines with a short interval between first and second vaccination or those showing full protection after a single vaccination may be preferable. Importantly, in the presence of circulating B cells also a humoral immune response may be expected despite prior RTX therapy.

Michael Markus Bonelli,1,2 Daniel Mrak,1 Thomas Perkmann,2 Helmuth Haslacher,2 Daniel Aletaha2 1Division of Rheumatology, Medical University of Vienna, Vienna, Austria 2Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

Correspondence to Professor Daniel Aletaha, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; daniel.aletaha@meduniwien.ac.at

Handling editor Gerd-Rüdiger B Hurmester

Acknowledgements We would like to thank all the patients who participated. We would also like to thank Patrick Mucher, Astrid Radakovics and Manuela Repli for perfect technical assistance.

Contributors All authors contributed to manuscript preparation. MM and DA contributed to the study design. TP and HH contributed to antibody measurement.

Funding We do not declare a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. However, the QuantIFERON SARS-CoV-2 RUO was kindly provided by the manufacturer (Qiagen).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Ethical approval for this study was granted by the local ethics committee of the Medical University of Vienna, Austria. Patients gave written informed consent to participate in the study and agreed that the findings of the study will be published in a scientific journal.

Provenance and peer review Not commissioned; externally peer reviewed.

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

© Author(s) (or their employer(s)) 2021. No commercial reuse. See rights and permissions. Published by BMJ.

Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/annrheumdis-2021-220408).


Received 20 March 2021
Revised 23 April 2021
Accepted 26 April 2021
Published Online First 6 May 2021


ORCID iDs Michael Markus Bonelli http://orcid.org/0000-0002-6122-7482 Daniel Aletaha http://orcid.org/0000-0003-2108-0030

REFERENCES
Methods

Patients:

Patients followed routinely at our outpatient clinic were enrolled. A detailed patients characteristics can be found in supplemental table S1. Prior to SARS-CoV-2 vaccination, the treatment duration with Rituximab was on average 27 months, the mean number of Rituximab cycles administered per patient was 5.8. Blood was drawn during routine screening laboratory testing. Serum samples were stored at the Biobank of the Medical University of Vienna, a centralized facility for the preparation and storage of biomaterial with certified quality management (ISO 9001:2015)[1]. Ethical approval for this study was granted by the local ethics committee of the Medical University of Vienna, Austria. All control participants provided written informed consent to donate their samples for the evaluation of diagnostic tests in the course of a Healthy Donor Collection of the MedUni Wien Biobank (EK 404/2011).

Patient and public involvement:

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Anti-SARS-CoV-2 testing:

The Elecsys® Anti-SARS-CoV-2 S immunoassay was used for the quantitative determination of antibodies to the receptor-binding domain (RBD) of the viral spike (S) protein[2]. The quantitation range is between 0.4 and 2500.0 U/mL. Previous SARS-CoV-2 infection was ruled out by measuring nucleocapsid-specific antibodies with the qualitative Elecsys Anti-SARS-CoV-2 assay[3]. Both tests were performed on a cobas® e801 analyzer (Roche Diagnostics, Rotkreuz, Switzerland) at the Department of Laboratory Medicine, Medical University of Vienna (certified acc. to ISO 9001:2015 and accredited acc. to ISO 15189:2012).

Assessment of SARS-CoV-2 specific T cell reactivity:

T cell reactivity to SARS-CoV-2 specific antigens was assessed by a commercially
available interferon-γ (IFN-γ)-release assay (QuantiFERON® SARS-CoV-2 RUO, Qiagen, Hilden, Germany). In brief, 1mL of heparinized whole blood was incubated at a mean of 6h (range 4-7h) after blood collection at 37±1°C for 22 hours in each of four different tubes: a so called Mitogen tube containing a non-specific T cell stimulator served as a positive control; a Nil tube without any additives served as a negative control; two further tubes contained with different SARS-CoV-2-specific antigen mixes for stimulation of lymphocytes involved in cell-mediated immunity. After incubation, samples were centrifuged and plasma was stored at <-70°C until analysis. IFN-γ was subsequently quantified using a QuantiFERON® IFN-γ ELISA (Qiagen), applying an 8-point standard curve. Results were calculated from optical density values using the QuantiFERON® R&D software v5.3.0 (Qiagen). Results exceeding the standard curve were interpreted as >8.0 U/mL IU/mL. The IFN-γ levels obtained from the Mitogen and SARS-CoV-2 specific tubes were corrected for the background measured in Nil tubes. According to tuberculosis testing recommendations Nil-values <0.7 IU/mL and Mitogen - Nil values ≥0.5 IU/mL were applied as reference standards.
Supplemental Table S1: patient’s characteristics

<table>
<thead>
<tr>
<th></th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>sex</strong></td>
<td>female</td>
<td>male</td>
<td>male</td>
<td>female</td>
<td>female</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>28</td>
<td>71</td>
<td>73</td>
<td>45</td>
<td>49</td>
</tr>
<tr>
<td><strong>diagnosis</strong></td>
<td>IMNM</td>
<td>AAV</td>
<td>EGPA</td>
<td>SLE</td>
<td>MCTD</td>
</tr>
<tr>
<td><strong>Major organ manifestations</strong></td>
<td>Myositis</td>
<td>NSIP</td>
<td>Peripheral neuropathy, cardiac involvement, asthma</td>
<td>Arthritis, Tenosynovitis, Polyserositis</td>
<td>ILD (NSIP), Raynaud Syndrome, Esophageal motility disorder, Microstomia</td>
</tr>
<tr>
<td><strong>Current disease specific therapies in addition to RTX</strong></td>
<td>MMF 2G, Prednisone 10mg, Immunoglobulin therapy q4w</td>
<td>Prednisone 2.5mg</td>
<td>none</td>
<td>Methotrexate 5mg</td>
<td>MMF 2.5 G, Prednisone 2.5mg</td>
</tr>
</tbody>
</table>

SLE: Systemic Lupus Erythematosus; MCTD: Mixed Connective Tissue Disease, EGPA: Eosinophilic granulomatosis with polyangiitis, IMNM: Immune-Mediated Necrotizing Myopathy, AAV: antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ILD: Interstitial Lung Disease, NSIP: Nonspecific interstitial Pneumonia, MMF: Mycophenolate Mofetil, q4w: every 4 weeks
<table>
<thead>
<tr>
<th>Patient</th>
<th>Hemoglobin g/dl (12-16)</th>
<th>Thrombocytes G/L (150-350)</th>
<th>Leukocytes G/L (4-10)</th>
<th>Lymphocytes %</th>
<th>CD3+ % (63 – 85)</th>
<th>CD3+CD4+ % (31 – 64)</th>
<th>CD3+CD8+ % (19 – 48)</th>
<th>CD3*HLA-DR+ % (3 – 17)</th>
<th>CD3*16&amp;56+ % (5 - 27)</th>
<th>CD19+ %</th>
<th>Monocytes %</th>
<th>Granulocytes %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>11.0</td>
<td>213</td>
<td>2.41</td>
<td>15</td>
<td>52</td>
<td>27</td>
<td>23</td>
<td>4</td>
<td>6</td>
<td>&lt;0.1</td>
<td>7</td>
<td>78</td>
</tr>
<tr>
<td>Patient 2</td>
<td>14.1</td>
<td>197</td>
<td>13.55</td>
<td>18</td>
<td>98</td>
<td>27</td>
<td>70</td>
<td>43</td>
<td>31</td>
<td>1</td>
<td>7</td>
<td>75</td>
</tr>
<tr>
<td>Patient 3</td>
<td>12.9</td>
<td>187</td>
<td>2.88</td>
<td>20</td>
<td>80</td>
<td>51</td>
<td>27</td>
<td>16</td>
<td>3</td>
<td>2</td>
<td>9</td>
<td>71</td>
</tr>
<tr>
<td>Patient 4</td>
<td>13.8</td>
<td>160</td>
<td>6.37</td>
<td>33</td>
<td>91</td>
<td>43</td>
<td>49</td>
<td>19</td>
<td>14</td>
<td>&lt;0.1</td>
<td>6</td>
<td>61</td>
</tr>
<tr>
<td>Patient 5</td>
<td>13.4</td>
<td>376</td>
<td>9.02</td>
<td>16</td>
<td>92</td>
<td>65</td>
<td>27</td>
<td>8</td>
<td>3</td>
<td>&lt;0.1</td>
<td>11</td>
<td>72</td>
</tr>
</tbody>
</table>

Supplemental table S2: Laboratory variables
References


Figure legends

Supplemental Figure 1: Timeline of measurement of SARS-CoV2- antibody and T cell response in patients treated with Rituximab.

Supplemental Figure 2: T cell mediated immune response in Rituximab treated patients.

T cell reactivity to SARS-CoV-2 specific antigens was assessed by an IFN-\(\gamma\) releasing assay. IFN-\(\gamma\) levels were measured after stimulation with unspecific Mitogen or two different SARS-CoV-2-specific antigen mixes (Ag1, Ag2). Rituximab treated patients with detectable antibodies against the receptor-binding domain of the viral spike protein are labeled in green. Patients with no detectable antibodies are labeled in blue. Vaccinated and not vaccinated healthy individuals served as a positive and negative control group.